Parkinson's drug setback hits Acorda stock hard

30 August 2017

More than 24% was taken off the market value of neurological disorders specialist Acorda Therapeutics (Nasdaq: ACOR) on Tuesday after the company received a Refusal to File (RTF) letter from the US Food and Drug Administration (FDA) regarding its New Drug Application (NDA) for Inbrija (levodopa inhalation powder).

Inbrija is an investigational treatment for symptoms of ‘off’ periods in people with Parkinson’s disease taking a carbidopa/levodopa regimen.

The FDA ruled that Acorda’s NDA was not sufficiently complete to permit a substantive review, saying that the company had failed to state when the manufacturing site would be ready for inspection. The agency also raised a question regarding the submission of the drug master production record, and has asked for additional information at resubmission, which was not part of the basis for the RTF.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK